Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALNY Stock Forecast 2026-2027
$308.43
Current Price
$41.15B
Market Cap
Buy 20
Hold 8
Sell 0
Wall St Analyst Ratings
Distance to ALNY Price Targets
+83.5%
To High Target of $566.00
+45.9%
To Median Target of $450.00
+0.5%
To Low Target of $310.00
ALNY Price Momentum
-7.5%
1 Week Change
-1.2%
1 Month Change
+30.3%
1 Year Change
-22.4%
Year-to-Date Change
-37.8%
From 52W High of $495.55
+35.1%
From 52W Low of $228.28
📊 TOP ANALYST CALLS
Did ALNY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Alnylam is one of their latest high-conviction picks.
Latest ALNY Stock Price Targets & Analyst Predictions
Based on our analysis of 50 Wall Street analysts, ALNY has a bullish consensus with a median price target of $450.00 (ranging from $310.00 to $566.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $308.43, the median forecast implies a 45.9% upside. This outlook is supported by 20 Buy, 8 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Salveen Richter at Goldman Sachs, projecting a 83.5% upside. Conversely, the most conservative target is provided by Luca Issi at RBC Capital, suggesting a 0.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALNY Analyst Ratings
20
Buy
8
Hold
0
Sell
ALNY Price Target Range
Low
$310.00
Average
$450.00
High
$566.00
Current: $308.43
Latest ALNY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALNY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 13, 2026 | Truist Securities | Danielle Brill | Buy | Maintains | $505.00 |
| Mar 25, 2026 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $510.00 |
| Mar 25, 2026 | Chardan Capital | Keay Nakae | Buy | Maintains | $425.00 |
| Mar 16, 2026 | Jefferies | Faisal Khurshid | Hold | Downgrade | $330.00 |
| Feb 18, 2026 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $510.00 |
| Feb 17, 2026 | Freedom Capital Markets | Ilya Zubkov | Buy | Upgrade | $410.00 |
| Feb 17, 2026 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $429.00 |
| Feb 17, 2026 | Freedom Broker | Buy | Upgrade | $N/A | |
| Feb 13, 2026 | Chardan Capital | Keay Nakae | Buy | Maintains | $425.00 |
| Feb 12, 2026 | Needham | Joseph Stringer | Buy | Maintains | $510.00 |
| Jan 30, 2026 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $462.00 |
| Jan 30, 2026 | Morgan Stanley | Michael Ulz | Equal-Weight | Maintains | $408.00 |
| Jan 30, 2026 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Maintains | $510.00 |
| Jan 28, 2026 | Barclays | Eliana Merle | Overweight | Initiates | $527.00 |
| Jan 20, 2026 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $376.00 |
| Jan 20, 2026 | RBC Capital | Luca Issi | Outperform | Maintains | $465.00 |
| Jan 12, 2026 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $529.00 |
| Jan 12, 2026 | Needham | Joseph Stringer | Buy | Maintains | $529.00 |
| Jan 8, 2026 | Truist Securities | Danielle Brill | Buy | Maintains | $530.00 |
| Dec 15, 2025 | Leerink Partners | Mani Foroohar | Market Perform | Maintains | $351.00 |
Alnylam Pharmaceuticals Inc. (ALNY) Competitors
The following stocks are similar to Alnylam based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alnylam Pharmaceuticals Inc. (ALNY) Financial Data
Alnylam Pharmaceuticals Inc. has a market capitalization of $41.15B with a P/E ratio of 134.0x. The company generates $3.71B in trailing twelve-month revenue with a 8.4% profit margin.
Revenue growth is +84.9% quarter-over-quarter, while maintaining an operating margin of +12.0% and return on equity of +73.3%.
Valuation Metrics
Market Cap
$41.15B
Enterprise Value
$41.13B
P/E Ratio
134.0x
PEG Ratio
22.0x
Price/Sales
11.2x
Growth & Margins
Revenue Growth (YoY)
+84.9%
Gross Margin
+75.6%
Operating Margin
+12.0%
Net Margin
+8.4%
EPS Growth
+84.9%
Financial Health
Cash/Price Ratio
+7.1%
Current Ratio
2.8x
Debt/Equity
376.2x
ROE
+73.3%
ROA
+6.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Alnylam Pharmaceuticals Inc. (ALNY) Business Model
About Alnylam Pharmaceuticals Inc.
What They Do
Develops RNA interference-based therapeutics.
Business Model
The company generates revenue through the development and commercialization of RNAi therapeutics. Its innovative approach targets specific messenger RNAs to silence disease-causing proteins, addressing unmet medical needs. Alnylam collaborates with major pharmaceutical partners and holds foundational patents that support its unique technology.
Additional Information
Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals has a robust pipeline focused on treating rare and prevalent genetic diseases. The company is positioned as a leader in gene-based drug discovery, utilizing strategic alliances to enhance its research and development capabilities.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
2,500
CEO
Dr. Yvonne L. Greenstreet M.B.A., M.D.
Country
United States
IPO Year
2004
Website
www.alnylam.comAlnylam Pharmaceuticals Inc. (ALNY) Latest News & Analysis
Latest News
Quick Summary
Alnylam Pharmaceuticals will report Q1 2026 financial results on April 30, 2026, before market open, with a conference call at 8:30 am ET to discuss the results and future expectations.
Why It Matters
Alnylam Pharmaceuticals' upcoming financial results and management update could impact stock performance, providing insights into growth potential and future strategies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Netflix excelled as worries over a Warner Bros. Discovery acquisition eased. Microsoft underperformed due to Azure growth concerns. Alnylam Pharmaceuticals shows promise for long-term growth.
Why It Matters
Netflix's strong performance alleviates acquisition fears, potentially boosting its stock. Microsoft faces scrutiny over Azure growth, impacting sentiment. Alnylam's promising pipeline suggests long-term value.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Investors should monitor ALNY stock due to recent activity in the options market, indicating potential changes in investor sentiment or stock volatility.
Why It Matters
Movements in the options market for ALNY stock signal potential volatility or shifts in investor sentiment, affecting stock price and investment strategies.
Source: Zacks Investment Research
Market Sentiment:
Neutral
An S&P 500 change may be imminent. These stocks are leading contenders to join the index.
16 days ago
Quick Summary
Hologic's upcoming acquisition may lead to Marvell, Alnylam, and Veeva being considered as potential replacements, according to an analyst.
Why It Matters
Hologic's acquisition may affect index compositions, prompting shifts in investment strategies towards Marvell, Alnylam, and Veeva as potential beneficiaries.
Source: Market Watch
Market Sentiment:
Positive
Quick Summary
Oncology mergers and acquisitions are increasing as major pharmaceutical firms aim to replenish their pipelines and invest in next-generation therapies.
Why It Matters
Accelerating oncology M&A signals potential growth opportunities and innovation, impacting stock valuations and investor sentiment in the pharmaceutical sector.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Quick Summary
Alnylam Pharmaceuticals presented new clinical and real-world data at ACC.26, highlighting the effectiveness of its RNAi therapeutics for cardiovascular disease patients.
Why It Matters
The announcement of new clinical data from Alnylam Pharmaceuticals enhances its credibility in the RNAi space, potentially increasing investor confidence and impacting stock performance in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ALNY Stock
What is Alnylam Pharmaceuticals Inc.'s (ALNY) stock forecast for 2026?
Based on our analysis of 50 Wall Street analysts, Alnylam Pharmaceuticals Inc. (ALNY) has a median price target of $450.00. The highest price target is $566.00 and the lowest is $310.00.
Is ALNY stock a good investment in 2026?
According to current analyst ratings, ALNY has 20 Buy ratings, 8 Hold ratings, and 0 Sell ratings. The stock is currently trading at $308.43. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALNY stock?
Wall Street analysts predict ALNY stock could reach $450.00 in the next 12 months. This represents a 45.9% increase from the current price of $308.43. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alnylam Pharmaceuticals Inc.'s business model?
The company generates revenue through the development and commercialization of RNAi therapeutics. Its innovative approach targets specific messenger RNAs to silence disease-causing proteins, addressing unmet medical needs. Alnylam collaborates with major pharmaceutical partners and holds foundational patents that support its unique technology.
What is the highest forecasted price for ALNY Alnylam Pharmaceuticals Inc.?
The highest price target for ALNY is $566.00 from Salveen Richter at Goldman Sachs, which represents a 83.5% increase from the current price of $308.43.
What is the lowest forecasted price for ALNY Alnylam Pharmaceuticals Inc.?
The lowest price target for ALNY is $310.00 from Luca Issi at RBC Capital, which represents a 0.5% increase from the current price of $308.43.
What is the overall ALNY consensus from analysts for Alnylam Pharmaceuticals Inc.?
The overall analyst consensus for ALNY is bullish. Out of 50 Wall Street analysts, 20 rate it as Buy, 8 as Hold, and 0 as Sell, with a median price target of $450.00.
How accurate are ALNY stock price projections?
Stock price projections, including those for Alnylam Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 4:24 AM UTC